News Release

Challenges and opportunities of nanomedicines in clinical translation

Peer-Reviewed Publication

Compuscript Ltd

Announcing a new article publication for BIO Integration journal. In this article the authors Chunxiong Zheng, Mingqiang Li and Jianxun Ding from Sun Yat-sen University, Guangzhou, China and Changchun Institute of Applied Chemistry, Changchun, China discuss the challenges and opportunities of nanomedicines in clinical translation.

Researchers are rapidly gaining a much deeper understanding of the challenges and opportunities of nanomedicines allowing for improvements in disease treatment and improved patient survival.

Deep exploration of the connections between preclinical and clinical modeling will facilitate the development of unique animal-based disease models remarkably similar to the human pathological mechanism to elevate the accuracy of predicting therapeutic efficacy in human clinical trials. Integration of active-targeting ligands and smart stimuli-responsive materials as well as the bio?nano interface interactions will endow nanomedicines with advanced functionalities to pioneer new-concept nanoparticle-based drugs.

By overcoming the obstacles of controllable, reproducible, as well as scalable nanoparticle production, cost, and toxicity, the next generation of nanomedicines that are incorporated with unique molecular modules and therapeutic agents, including cell-based therapeutics, siRNA, mRNA, DNA, protein, and so forth, will be accelerated into clinical development.


Article reference: Chunxiong Zheng, Mingqiang Li and Jianxun Ding, Challenges and Opportunities of Nanomedicines in Clinical Translation. BIO Integration, 2021,

BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

BIOI is now open for submissions; articles can be submitted online at:

Please visit to learn more about the journal.

Editorial Board:

Please visit to learn more about the journal.

Editorial Board:

BIOI is available on the IngentaConnect platform ( and at the BIO Integration website (

Submissions may be made using ScholarOne (

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook ( and LinkedIn (

ISSN 2712-0074
eISSN 2712-0082

Keywords: nanomedicines; clinical translation

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.